Regulus Therapeutics Inc. (NASDAQ:RGLS) has received a consensus rating of “Hold” from the nine ratings firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and one has assigned a buy recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $3.00.

Several research firms have recently issued reports on RGLS. Chardan Capital reduced their target price on Regulus Therapeutics from $5.00 to $2.50 and set a “buy” rating for the company in a report on Tuesday, June 13th. Wedbush reaffirmed an “ourperform” rating and set a $4.00 target price on shares of Regulus Therapeutics in a research report on Monday, August 7th. Zacks Investment Research downgraded shares of Regulus Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, September 19th. Needham & Company LLC restated a “hold” rating on shares of Regulus Therapeutics in a research report on Wednesday, August 2nd. Finally, BMO Capital Markets set a $1.00 price target on shares of Regulus Therapeutics and gave the company a “hold” rating in a research report on Monday, June 12th.

In related news, CFO Daniel R. Chevallard acquired 54,945 shares of the company’s stock in a transaction that occurred on Tuesday, July 25th. The shares were acquired at an average price of $0.91 per share, with a total value of $49,999.95. Following the acquisition, the chief financial officer now owns 59,415 shares of the company’s stock, valued at approximately $54,067.65. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director William H. Rastetter acquired 274,725 shares of the company’s stock in a transaction that occurred on Tuesday, July 25th. The shares were bought at an average cost of $0.91 per share, for a total transaction of $249,999.75. The disclosure for this purchase can be found here. Insiders have purchased a total of 549,450 shares of company stock worth $500,000 over the last 90 days. 4.80% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently bought and sold shares of RGLS. EcoR1 Capital LLC increased its position in shares of Regulus Therapeutics by 145.6% during the second quarter. EcoR1 Capital LLC now owns 3,709,144 shares of the biopharmaceutical company’s stock valued at $3,656,000 after buying an additional 2,199,144 shares during the period. Goldman Sachs Group Inc. boosted its position in shares of Regulus Therapeutics by 189.1% in the second quarter. Goldman Sachs Group Inc. now owns 368,285 shares of the biopharmaceutical company’s stock valued at $363,000 after acquiring an additional 240,890 shares during the period. South Dakota Investment Council boosted its position in shares of Regulus Therapeutics by 16.3% in the first quarter. South Dakota Investment Council now owns 1,327,058 shares of the biopharmaceutical company’s stock valued at $2,190,000 after acquiring an additional 186,130 shares during the period. LMR Partners LLP bought a new position in shares of Regulus Therapeutics in the second quarter valued at approximately $164,000. Finally, GSA Capital Partners LLP bought a new position in shares of Regulus Therapeutics in the second quarter valued at approximately $139,000. 21.92% of the stock is owned by institutional investors and hedge funds.

Regulus Therapeutics (RGLS) traded up 5.60% during mid-day trading on Wednesday, hitting $1.32. The stock had a trading volume of 2,880,636 shares. Regulus Therapeutics has a 1-year low of $0.79 and a 1-year high of $3.65. The stock’s market cap is $137.00 million. The firm’s 50-day moving average price is $1.10 and its 200-day moving average price is $1.24.

Regulus Therapeutics (NASDAQ:RGLS) last posted its earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by ($0.10). Regulus Therapeutics had a negative return on equity of 173.20% and a negative net margin of 31,460.47%. The firm had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.02 million. On average, equities analysts expect that Regulus Therapeutics will post ($1.02) earnings per share for the current year.

WARNING: This piece of content was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/analysts-set-regulus-therapeutics-inc-rgls-pt-at-3-00/1603959.html.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Analyst Recommendations for Regulus Therapeutics (NASDAQ:RGLS)

Receive News & Ratings for Regulus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.